title: Preclinical experiments on the release behavior of biodegradable nanofibrous multipharmaceutical membranes in a model of four-wall intrabony defect.
abstract: Guided tissue regeneration (GTR) therapy has been widely used to regenerate lost periodontium from periodontal disease. However, in terms of regenerative periodontal therapy, a multidrug-loaded biodegradable carrier can be even more promising in dealing with periodontal disease. In the current study, we fabricated biodegradable nanofibrous collagen membranes that were loaded with amoxicillin, metronidazole, and lidocaine by an electrospinning technique. The in vitro release behavior and the cytotoxicity of the membranes were investigated. A four-wall intrabony defect was created in rabbits for in vivo release analysis. The bioactivity of the released antibiotics was also examined. The experimental results showed that the drug-loaded collagen membranes could provide sustainable release of effective amoxicillin, metronidazole, and lidocaine for 28, 56, and 8 days, respectively, in vivo. Furthermore, the bioactivity of the released antibiotics remained high, with average bioactivities of 50.5% for amoxicillin against Staphylococcus aureus and 58.6% for metronidazole against Escherichia coli. The biodegradable nanofibrous multipharmaceutical membranes developed in this study may provide a promising solution for regenerative periodontal therapy.
authors.affiliation: Department of Orthopedic Surgery, Chang Gung Memorial Hospital, Kwei-Shan, Tao-Yuan, Taiwan.
authors.forename: Dave Wei-Chih
authors.initials: DW
authors.lastname: Chen
authors.forename: Fu-Ying
authors.initials: FY
authors.lastname: Lee
authors.forename: Jun-Yi
authors.initials: JY
authors.lastname: Liao
authors.forename: Shih-Jung
authors.initials: SJ
authors.lastname: Liu
authors.forename: Chao-Ying
authors.initials: CY
authors.lastname: Hsiao
authors.forename: Jan-Kan
authors.initials: JK
authors.lastname: Chen
mesh_terms: D000658:Amoxicillin / Q000493:pharmacokinetics* / Q000494:pharmacology; D000818:Animals; D000900:Anti-Bacterial Agents / Q000493:pharmacokinetics* / Q000494:pharmacology; D001672:Biocompatible Materials / Q000737:chemistry* / Q000494:pharmacology; D044963:Biopsy, Fine-Needle; D002470:Cell Survival / Q000187:drug effects; D003094:Collagen / Q000737:chemistry; D003692:Delayed-Action Preparations / Q000737:chemistry* / Q000494:pharmacology; D004353:Drug Evaluation, Preclinical; D055664:Electrochemical Techniques; D004926:Escherichia coli / Q000187:drug effects / Q000254:growth & development; D005347:Fibroblasts / Q000166:cytology / Q000187:drug effects; D048091:Guided Tissue Regeneration / Q000379:methods*; D006801:Humans; D008012:Lidocaine / Q000493:pharmacokinetics* / Q000494:pharmacology; D008795:Metronidazole / Q000493:pharmacokinetics* / Q000494:pharmacology; D008826:Microbial Sensitivity Tests; D011817:Rabbits; D013211:Staphylococcus aureus / Q000187:drug effects / Q000254:growth & development; D013977:Tibia / Q000187:drug effects / Q000601:surgery
chemical_list: D000900:Anti-Bacterial Agents; D001672:Biocompatible Materials; D003692:Delayed-Action Preparations; D008795:Metronidazole; D000658:Amoxicillin; D003094:Collagen; D008012:Lidocaine